Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)

NCT ID: NCT00141193

Last Updated: 2008-08-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1561 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-02-28

Study Completion Date

2007-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a prospective, randomized, double-blind, placebo-controlled, multi-center trial to compare the efficacy and safety of celecoxib 400mg QD versus placebo in reducing the occurrence of new colorectal adenomas post-polypectomy at Month 13 (Year 1) and Month 37 (Year 3) of study drug administration.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Adenoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Group Type PLACEBO_COMPARATOR

Celecoxib

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Celecoxib

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The subject has had a documented colonoscopy to the cecum performed by a study-related physician with adequate preparation resulting in diagnosis and clearance of an adenomatous polyp(s) within 4 months prior to randomization.
* The subject is willing to abstain from chronic use of all NSAIDs or COX-2 inhibitors excluding aspirin at cardioprotective doses for the duration of the study.

Exclusion Criteria

* The subject has a history of Familial Adenomatous Polyposis or Hereditary Non-Polyposis Colorectal Cancer.
* The subject has a history of inflammatory bowel disease.
Minimum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pfizer Inc

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

San Diego, California, United States

Site Status

Pfizer Investigational Site

San Kiego, California, United States

Site Status

Pfizer Investigational Site

North Chicago, Illinois, United States

Site Status

Pfizer Investigational Site

Oak Park, Illinois, United States

Site Status

Pfizer Investigational Site

Baltimore, Maryland, United States

Site Status

Pfizer Investigational Site

Baltimore, Maryland, United States

Site Status

Pfizer Investigational Site

Philadelphia, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Philadelphia, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Houston, Texas, United States

Site Status

Pfizer Investigational Site

Richmond, Virginia, United States

Site Status

Pfizer Investigational Site

Townsville, Queensland, Australia

Site Status

Pfizer Investigational Site

Geelong, Victoria, Australia

Site Status

Pfizer Investigational Site

Brussels, , Belgium

Site Status

Pfizer Investigational Site

Brussels, , Belgium

Site Status

Pfizer Investigational Site

Brussels, , Belgium

Site Status

Pfizer Investigational Site

Ghent, , Belgium

Site Status

Pfizer Investigational Site

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Pfizer Investigational Site

São Paulo, São Paulo, Brazil

Site Status

Pfizer Investigational Site

Edmonton, Alberta, Canada

Site Status

Pfizer Investigational Site

Abbotsford, British Columbia, Canada

Site Status

Pfizer Investigational Site

Vancouver, British Columbia, Canada

Site Status

Pfizer Investigational Site

Vancouver, British Columbia, Canada

Site Status

Pfizer Investigational Site

Kingston, Ontario, Canada

Site Status

Pfizer Investigational Site

London, Ontario, Canada

Site Status

Pfizer Investigational Site

St. John's, , Canada

Site Status

Pfizer Investigational Site

Santiago, RM, Chile

Site Status

Pfizer Investigational Site

Beijing, , China

Site Status

Pfizer Investigational Site

Beijing, , China

Site Status

Pfizer Investigational Site

Brno, , Czechia

Site Status

Pfizer Investigational Site

Hradec Králové, , Czechia

Site Status

Pfizer Investigational Site

Liberec, , Czechia

Site Status

Pfizer Investigational Site

Prague, , Czechia

Site Status

Pfizer Investigational Site

Prague, , Czechia

Site Status

Pfizer Investigational Site

Prague, , Czechia

Site Status

Pfizer Investigational Site

Prague, , Czechia

Site Status

Pfizer Investigational Site

Arhus C, , Denmark

Site Status

Pfizer Investigational Site

Oulu, , Finland

Site Status

Pfizer Investigational Site

Bobigny, , France

Site Status

Pfizer Investigational Site

Lyon, , France

Site Status

Pfizer Investigational Site

Marseille, , France

Site Status

Pfizer Investigational Site

Paris, , France

Site Status

Pfizer Investigational Site

Berlin, , Germany

Site Status

Pfizer Investigational Site

Erlangen, , Germany

Site Status

Pfizer Investigational Site

Freising, , Germany

Site Status

Pfizer Investigational Site

Hamburg, , Germany

Site Status

Pfizer Investigational Site

Künzing, , Germany

Site Status

Pfizer Investigational Site

Ludwigshafen, , Germany

Site Status

Pfizer Investigational Site

Marburg, , Germany

Site Status

Pfizer Investigational Site

München, , Germany

Site Status

Pfizer Investigational Site

München, , Germany

Site Status

Pfizer Investigational Site

Ulm, , Germany

Site Status

Pfizer Investigational Site

Hong Kong, , Hong Kong

Site Status

Pfizer Investigational Site

New Territories, , Hong Kong

Site Status

Pfizer Investigational Site

Győr, , Hungary

Site Status

Pfizer Investigational Site

Szekszárd, , Hungary

Site Status

Pfizer Investigational Site

Wilton, Cork, Ireland

Site Status

Pfizer Investigational Site

Dublin, , Ireland

Site Status

Pfizer Investigational Site

Beer-Sheeva, , Israel

Site Status

Pfizer Investigational Site

Hadera, , Israel

Site Status

Pfizer Investigational Site

Haifa, , Israel

Site Status

Pfizer Investigational Site

Hashomer, , Israel

Site Status

Pfizer Investigational Site

Holon, , Israel

Site Status

Pfizer Investigational Site

Jerusalem, , Israel

Site Status

Pfizer Investigational Site

Petah Tikva, , Israel

Site Status

Pfizer Investigational Site

Tel Aviv, , Israel

Site Status

Pfizer Investigational Site

San Giovanni Rotondo, Italy/Foggia/Italy, Italy

Site Status

Pfizer Investigational Site

Brescia, , Italy

Site Status

Pfizer Investigational Site

Milan, , Italy

Site Status

Pfizer Investigational Site

Roma, , Italy

Site Status

Pfizer Investigational Site

Roma, , Italy

Site Status

Pfizer Investigational Site

Siena, , Italy

Site Status

Pfizer Investigational Site

Maastricht, , Netherlands

Site Status

Pfizer Investigational Site

Skien, , Norway

Site Status

Pfizer Investigational Site

Lima, Lima Province, Peru

Site Status

Pfizer Investigational Site

Warsaw, , Poland

Site Status

Pfizer Investigational Site

Lisbon, , Portugal

Site Status

Pfizer Investigational Site

Moscow, , Russia

Site Status

Pfizer Investigational Site

Moscow, , Russia

Site Status

Pfizer Investigational Site

Moscow, , Russia

Site Status

Pfizer Investigational Site

Moscow, , Russia

Site Status

Pfizer Investigational Site

Moscow, , Russia

Site Status

Pfizer Investigational Site

Moscow, , Russia

Site Status

Pfizer Investigational Site

Singapore, , Singapore

Site Status

Pfizer Investigational Site

Singapore, , Singapore

Site Status

Pfizer Investigational Site

Bratislava, , Slovakia

Site Status

Pfizer Investigational Site

Bratislava, , Slovakia

Site Status

Pfizer Investigational Site

Johannesburg, Gauteng, South Africa

Site Status

Pfizer Investigational Site

Johannesburg, Gauteng, South Africa

Site Status

Pfizer Investigational Site

Johannesburg, Gauteng, South Africa

Site Status

Pfizer Investigational Site

Cape Town, Western, South Africa

Site Status

Pfizer Investigational Site

Palma de Mallorca, Balearic Islands, Spain

Site Status

Pfizer Investigational Site

Barcelona, Barcelona, Spain

Site Status

Pfizer Investigational Site

Donostia / San Sebastian, Guipuzcoa, Spain

Site Status

Pfizer Investigational Site

Oviedo, Principality of Asturias, Spain

Site Status

Pfizer Investigational Site

Seville, Sevilla, Spain

Site Status

Pfizer Investigational Site

Stockholm, , Sweden

Site Status

Pfizer Investigational Site

Uppsala, , Sweden

Site Status

Pfizer Investigational Site

Geneva, , Switzerland

Site Status

Pfizer Investigational Site

Kaohsiung City, , Taiwan

Site Status

Pfizer Investigational Site

Newport, Gwent, United Kingdom

Site Status

Pfizer Investigational Site

Harrow, Middlesex, United Kingdom

Site Status

Pfizer Investigational Site

Glasgow, , United Kingdom

Site Status

Pfizer Investigational Site

Oxford, , United Kingdom

Site Status

Pfizer Investigational Site

Montevideo, , Uruguay

Site Status

Pfizer Investigational Site

Montevideo, , Uruguay

Site Status

Pfizer Investigational Site

Montevideo, , Uruguay

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Belgium Brazil Canada Chile China Czechia Denmark Finland France Germany Hong Kong Hungary Ireland Israel Italy Netherlands Norway Peru Poland Portugal Russia Singapore Slovakia South Africa Spain Sweden Switzerland Taiwan United Kingdom Uruguay

References

Explore related publications, articles, or registry entries linked to this study.

Arber N, Lieberman D, Wang TC, Zhang R, Sands GH, Bertagnolli MM, Hawk ET, Eagle C, Coindreau J, Zauber A, Lanas A, Levin B. The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo. Clin Ther. 2012 Mar;34(3):569-79. doi: 10.1016/j.clinthera.2012.02.001. Epub 2012 Mar 2.

Reference Type DERIVED
PMID: 22386831 (View on PubMed)

Arber N, Spicak J, Racz I, Zavoral M, Breazna A, Gerletti P, Lechuga MJ, Collins N, Rosenstein RB, Eagle CJ, Levin B. Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial. Am J Gastroenterol. 2011 Jun;106(6):1135-46. doi: 10.1038/ajg.2011.116. Epub 2011 Apr 19.

Reference Type DERIVED
PMID: 21503000 (View on PubMed)

Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E; Cross Trial Safety Assessment Group. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008 Apr 22;117(16):2104-13. doi: 10.1161/CIRCULATIONAHA.108.764530. Epub 2008 Mar 31.

Reference Type DERIVED
PMID: 18378608 (View on PubMed)

Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B; PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006 Aug 31;355(9):885-95. doi: 10.1056/NEJMoa061652.

Reference Type DERIVED
PMID: 16943401 (View on PubMed)

Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N, Wittes J; APC and PreSAP Trial Investigators. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006 Sep 5;114(10):1028-35. doi: 10.1161/CIRCULATIONAHA.106.636746.

Reference Type DERIVED
PMID: 16943394 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A3191107

Identifier Type: -

Identifier Source: secondary_id

EQ4-00-02-018

Identifier Type: -

Identifier Source: org_study_id